FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213362168> ?p ?o ?g. }

• W4213362168 endingPage "273" @default.
• W4213362168 startingPage "257" @default.
• W4213362168 abstract "Etoposide is regarded as one of the main standard cytotoxic drugs for lung cancer. However, mutations in Kelch-like ECH-associated protein 1 (Keap1), the main regulator of nuclear factor erythroid 2-related factor 2 (Nrf2), are often detected in lung cancer and lead to chemoresistance. Since the aberrant activation of Nrf2 enhances drug resistance, the suppression of the Nrf2 pathway is a promising therapeutic strategy for lung cancer. We herein used the human lung adenocarcinoma cell line A549 because it harbors a Keap1 loss-of-function mutation. A treatment with β-glucan, a major component of the fungal cell wall, reduced Nrf2 protein levels; downregulated the expression of cytochrome P450 3A5, UDP glucuronosyltransferase 1A1, and multidrug resistance protein 1; and increased etoposide sensitivity in A549 cells. Furthermore, the ephrin type-A receptor 2 (EphA2) receptor was important for the recognition and biologic activity of β-glucan in A549 cells. EphA2 signaling includes nuclear factor kappa B (NF-κB), signal transducer and activator of transcription 3 (STAT3), and p38 mitogen-activated protein kinase (MAPK). However, treatment of cells with stattic (STAT3 inhibitor) or SB203580 (p38 MAPK inhibitor) did not diminish the effects of β-glucan. In contrast, knockdown of v-rel reticuloendotheliosis viral oncogene homolog B (RelB) abolished the effects of β-glucan, suggesting the involvement of the noncanonical NF-κB pathway. The β-glucan effects were also attenuated by the knockdown of WD40 Repeat protein 23 (WDR23). The β-glucan treatment and RelB overexpression induced the expression of Cullin-4A (CUL4A), which increased WDR23 ligase activity and promoted the subsequent depletion of Nrf2. These results revealed a novel property of β-glucan as a resistance-modifying agent in addition to its widely reported immunomodulatory effects for lung cancer therapy via the EphA2-RelB-CUL4A-Nrf2 axis. SIGNIFICANCE STATEMENT: Chemotherapeutic resistance remains a major obstacle in cancer therapy despite extensive efforts to elucidate the underlying molecular mechanisms and overcome multidrug resistance. The present study revealed a novel resistance-modifying property of β-glucan, thereby expanding our knowledge on the beneficial roles of β-glucan and providing an alternative strategy to prevent drug resistance by cancer. The present results provide evidence for the involvement of a novel mode of NF-κB and Nrf2 crosstalk in the drug resistance phenotype." @default.
• W4213362168 created "2022-02-24" @default.
• W4213362168 creator A5011522311 @default.
• W4213362168 creator A5043383672 @default.
• W4213362168 creator A5045181951 @default.
• W4213362168 creator A5062450020 @default.
• W4213362168 date "2022-02-22" @default.
• W4213362168 modified "2023-10-01" @default.
• W4213362168 title "Yeast <i>β</i>-glucan Increases Etoposide Sensitivity in Lung Cancer Cell Line A549 by Suppressing Nuclear Factor Erythroid 2-Related Factor 2 via the Noncanonical Nuclear Factor Kappa B Pathway" @default.
• W4213362168 cites W1019836896 @default.
• W4213362168 cites W1780888641 @default.
• W4213362168 cites W1843876269 @default.
• W4213362168 cites W1964296201 @default.
• W4213362168 cites W1972439337 @default.
• W4213362168 cites W1973731306 @default.
• W4213362168 cites W1979488290 @default.
• W4213362168 cites W1987051998 @default.
• W4213362168 cites W1994603958 @default.
• W4213362168 cites W1998689706 @default.
• W4213362168 cites W2007752971 @default.
• W4213362168 cites W2008415419 @default.
• W4213362168 cites W2009109694 @default.
• W4213362168 cites W2046878463 @default.
• W4213362168 cites W2048310781 @default.
• W4213362168 cites W2048379863 @default.
• W4213362168 cites W2055196208 @default.
• W4213362168 cites W2057626046 @default.
• W4213362168 cites W2060869284 @default.
• W4213362168 cites W2070164388 @default.
• W4213362168 cites W2071329976 @default.
• W4213362168 cites W2075775813 @default.
• W4213362168 cites W2094026727 @default.
• W4213362168 cites W2101540252 @default.
• W4213362168 cites W2104718696 @default.
• W4213362168 cites W2113024198 @default.
• W4213362168 cites W2128916257 @default.
• W4213362168 cites W2133584350 @default.
• W4213362168 cites W2136174128 @default.
• W4213362168 cites W2160888840 @default.
• W4213362168 cites W2161446823 @default.
• W4213362168 cites W2164949044 @default.
• W4213362168 cites W2169302611 @default.
• W4213362168 cites W2171937543 @default.
• W4213362168 cites W2232762837 @default.
• W4213362168 cites W2343448953 @default.
• W4213362168 cites W2507289596 @default.
• W4213362168 cites W2515118862 @default.
• W4213362168 cites W2563700945 @default.
• W4213362168 cites W2596418572 @default.
• W4213362168 cites W2608930323 @default.
• W4213362168 cites W2731058852 @default.
• W4213362168 cites W2784136961 @default.
• W4213362168 cites W2792886369 @default.
• W4213362168 cites W2793322448 @default.
• W4213362168 cites W2799542610 @default.
• W4213362168 cites W2801037469 @default.
• W4213362168 cites W2805735750 @default.
• W4213362168 cites W2900667951 @default.
• W4213362168 cites W2929813355 @default.
• W4213362168 cites W2940429062 @default.
• W4213362168 cites W2949823271 @default.
• W4213362168 cites W2962993133 @default.
• W4213362168 cites W2972606314 @default.
• W4213362168 cites W2990396305 @default.
• W4213362168 cites W3008964404 @default.
• W4213362168 cites W3014913757 @default.
• W4213362168 cites W3036369728 @default.
• W4213362168 cites W3044380747 @default.
• W4213362168 cites W3107569406 @default.
• W4213362168 cites W3119005666 @default.
• W4213362168 cites W3120115277 @default.
• W4213362168 cites W3156730323 @default.
• W4213362168 cites W3157104053 @default.
• W4213362168 cites W3158881329 @default.
• W4213362168 cites W4233573022 @default.
• W4213362168 doi "https://doi.org/10.1124/molpharm.121.000475" @default.
• W4213362168 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35193967" @default.
• W4213362168 hasPublicationYear "2022" @default.
• W4213362168 type Work @default.
• W4213362168 citedByCount "3" @default.
• W4213362168 countsByYear W42133621682022 @default.
• W4213362168 countsByYear W42133621682023 @default.
• W4213362168 crossrefType "journal-article" @default.
• W4213362168 hasAuthorship W4213362168A5011522311 @default.
• W4213362168 hasAuthorship W4213362168A5043383672 @default.
• W4213362168 hasAuthorship W4213362168A5045181951 @default.
• W4213362168 hasAuthorship W4213362168A5062450020 @default.
• W4213362168 hasBestOaLocation W42133621681 @default.
• W4213362168 hasConcept C153911025 @default.
• W4213362168 hasConcept C173396325 @default.
• W4213362168 hasConcept C190283241 @default.
• W4213362168 hasConcept C502942594 @default.
• W4213362168 hasConcept C55493867 @default.
• W4213362168 hasConcept C81729549 @default.
• W4213362168 hasConcept C86803240 @default.
• W4213362168 hasConceptScore W4213362168C153911025 @default.
• W4213362168 hasConceptScore W4213362168C173396325 @default.
• W4213362168 hasConceptScore W4213362168C190283241 @default.

• next